Wearable Bladder Modulation System
DeviceWearable Closed-Loop, Continuous Sensing Tibial Nerve Stimulation Device
NCT Number: NCT04547920
This is a prospective, multicenter study that was conducted to evaluate the safety and efficacy of a novel, closed-loop, continuous-sensing wearable neuromodulation system for Overactive Bladder symptom control.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Stanford University, Stanford, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Wearable Closed-Loop, Continuous Sensing Tibial Nerve Stimulation Device
Time frame: 12 Weeks
The percentage of responders in voiding (urinary frequency) events, where a responder is defined as a subject that either achieves a 50% or greater reduction, from baseline (Visit 1) to Week 12 (Visit 5), in total voids per day relative to an upper normal limit of 8 voids per day, or returns to normal (8 or fewer voids per day) at Week 12.
Time frame: 12 Weeks
Percentage of Responders in Incontinence (Leak) Events (IE), where a responder is defined as a subject that either achieves a 50% or greater reduction, from baseline (Visit 1) to Week 12 (Visit 5), in total incontinence events per day, or returns to normal (0 events per day), at Week 12.
Time frame: 12 Weeks
Percentage of Responders in Urgency Events (UE), where a responder is defined as a subject that either achieves a 50% or greater reduction, from baseline (Visit 1) to Week 12 (Visit 5), in total urgency events per day, or returns to normal (0 events per day) at Week 12.
Time frame: 12 Weeks
Overall Responder Rate at 12 Weeks, where responder is defined as any subject with a 50% or greater improvement, or return to normal, in the total number of voids per day, or the total number of urgency events/day, or the total number of leaks per day from baseline at Week 12.
Time frame: 12 Months
Overall Responder Rate at 12 Months, where responder is defined as any subject with a 50% or greater improvement, or return to normal, in the total number of voids per day, or the total number of urgency events/day, or the total number of leaks per day from baseline at 6 months.
Avation Medical, Inc.
Industry
A Prospective Efficacy Study Comparing FREquency of Use and Efficacy of a Personalized Surgery-free Wearable and Personalized Bladder Modulation System With Objective Confirmation of Nerve Activation for Use in the Home by Subjects With OverActive Bladder Syndrome
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05308979
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Orange, California, United States
View Trial DetailsNCT03625492
Alcohol Drinking, Behavior
Ann Arbor, Michigan, United States
View Trial DetailsNCT06695585
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Louisville, Kentucky, United States
View Trial DetailsNCT06198439
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Houston, Texas, United States
View Trial Details